Member Info for Notposting

I have feelings. 😆🫠

Well said, JRDC. Hear hear.

Please do. This should be enlightening 😆

Or read what matters https://hemogenyx.com/wp-content/uploads/2025/11/Hemogenyx-Pharmaceuticals-plc-Prospectus-20251119.pdf

Read the official prospectus pointing out the following…

Don't forget they may need manufacturing runs too and in my opinion it’s unlikely you see the next treatment till late Q1/ early Q2 but it’s unknown at this stage as to where they are with that so granted could be earlier.

To address this anticipated funding shortfall, the Group will require ADDITIONAL WORKING CAPITAL OF £5.6 MILLION BY THE END OF JANUARY 2026 just to continue its product development activities with a primary focus on HG-CT-1 through to the end of 2026. A FURTHER £10 MILLION will be required from 2027 to 2028.

The Group will have INSUFFICIENT WORKING CAPITAL AFTER ADMISSION and further funds WILL BE REQUIRED in the first quarter of 2026 simply to continue operations and complete Phase I trials of HG-CT-1 in adult and paediatric patients.

The Company states clearly that working capital will be INSUFFICIENT FOR ITS PRESENT REQUIREMENTS for at least the next 12 months. Following Admission, Directors expect an AGGREGATE FUNDING SHORTFALL OF £15.6 MILLION.

Hemotruth. Did you discuss this in your private group and how you can use it to fleece fellow shareholders again? 🫠

There will be no injection at this rate, because the company has confirmed it does not have the finances to continue trials without securing a further £5.6 million by January 2026.

And even if they manage to raise it, the injection is unlikely to happen before late Q1 or early Q2 at the very earliest.

Don't forget they may need manufacturing runs too.

To address this anticipated funding shortfall, the Group will require ADDITIONAL WORKING CAPITAL OF £5.6 MILLION BY THE END OF JANUARY 2026 just to continue its product development activities with a primary focus on HG-CT-1 through to the end of 2026. A FURTHER £10 MILLION will be required from 2027 to 2028.

The Group will have INSUFFICIENT WORKING CAPITAL AFTER ADMISSION and further funds WILL BE REQUIRED in the first quarter of 2026 simply to continue operations and complete Phase I trials of HG-CT-1 in adult and paediatric patients.

The Company states clearly that working capital will be INSUFFICIENT FOR ITS PRESENT REQUIREMENTS for at least the next 12 months. Following Admission, Directors expect an AGGREGATE FUNDING SHORTFALL OF £15.6 MILLION.

This is DESPITE THE MISLEADING HYPE AROUND A LOI IN ESTONIA and despite JustHereForFleecing being WRONG AGAIN yet still arguing with anyone who applies some sense.

They say: “The Company has incurred SIGNIFICANT LOSSES EVERY YEAR since its inception. The Company EXPECTS TO CONTINUE TO INCUR LOSSES OVER THE NEXT SEVERAL YEARS and MAY NEVER ACHIEVE OR MAINTAIN PROFITABILITY.”

Shicky. It clearly outlines the money will be used for the Made transfer and then they have insufficient funds to continue unless funds to the tune of £5.6m are raised. Something JustHereForFleecing mislead you all to believe there would be no signficant cost too, was “a simple address change” and would have no delays to the trials. All three incorrect.

Diggittt. Forgive me if I don’t hold much value in your opinion given your comments and support for the fleecers.

I’m fully aware of which parts are relevant and which parts are of interest. Clearly, you are not. They have insufficient capital to continue at the moment. Fact. £5.6m is needed. Fact.. it’s important. Fact.

INSUFFICIENT WORKING CAPITAL to continue. £5.6m required by January20 Nov 2025 20:41

There will be no injection at this rate, because the company has confirmed it does not have the finances to continue trials without securing a further £5.6 million by January 2026.

And even if they manage to raise it, the injection is unlikely to happen before late Q1 or early Q2 at the very earliest.

Don't forget they may need manufacturing runs too.

To address this anticipated funding shortfall, the Group will require ADDITIONAL WORKING CAPITAL OF £5.6 MILLION BY THE END OF JANUARY 2026 just to continue its product development activities with a primary focus on HG-CT-1 through to the end of 2026. A FURTHER £10 MILLION will be required from 2027 to 2028.

The Group will have INSUFFICIENT WORKING CAPITAL AFTER ADMISSION and further funds WILL BE REQUIRED in the first quarter of 2026 simply to continue operations and complete Phase I trials of HG-CT-1 in adult and paediatric patients.

The Company states clearly that working capital will be INSUFFICIENT FOR ITS PRESENT REQUIREMENTS for at least the next 12 months. Following Admission, Directors expect an AGGREGATE FUNDING SHORTFALL OF £15.6 MILLION.

This is DESPITE THE MISLEADING HYPE AROUND A LOI IN ESTONIA and despite JustHereForFleecing being WRONG AGAIN yet still arguing with anyone who applies some sense.

They say: “The Company has incurred SIGNIFICANT LOSSES EVERY YEAR since its inception. The Company EXPECTS TO CONTINUE TO INCUR LOSSES OVER THE NEXT SEVERAL YEARS and MAY NEVER ACHIEVE OR MAINTAIN PROFITABILITY.”

I agree. Shame you and your cohort have been doing that for so long, taking advantage during the placing, and continuing to manipulate it for your own gains, JustHereForFleecing.

You struggling to sleep? x

No need. JustHereForFleecing started that ramp a week or two ago on Reddit again when he bought back in for a trade 😆😆. He ended up getting ripped to shreds and called out by the US investors who saw right through him 😅 #internationalembarrassment

Here he is. 😆 alias after alias. Appropriate name for the WhatsApp group.

😆😆😆 yes, because that will solve the immediate issue of significant funding and make a huge difference to anything meaningful.

LOL.

There will be no injection at this rate, because the company has confirmed it does not have the finances to continue trials without securing a further £5.6 million by January 2026.

And even if they manage to raise it, the injection is unlikely to happen before late Q1 or early Q2 at the very earliest.

Don't forget they may need manufacturing runs too.

To address this anticipated funding shortfall, the Group will require ADDITIONAL WORKING CAPITAL OF £5.6 MILLION BY THE END OF JANUARY 2026 just to continue its product development activities with a primary focus on HG-CT-1 through to the end of 2026. A FURTHER £10 MILLION will be required from 2027 to 2028.

The Group will have INSUFFICIENT WORKING CAPITAL AFTER ADMISSION and further funds WILL BE REQUIRED in the first quarter of 2026 simply to continue operations and complete Phase I trials of HG-CT-1 in adult and paediatric patients.

The Company states clearly that working capital will be INSUFFICIENT FOR ITS PRESENT REQUIREMENTS for at least the next 12 months. Following Admission, Directors expect an AGGREGATE FUNDING SHORTFALL OF £15.6 MILLION.

This is DESPITE THE MISLEADING HYPE AROUND A LOI IN ESTONIA and despite JustHereForFleecing being WRONG AGAIN yet still arguing with anyone who applies some sense.

They say: “The Company has incurred SIGNIFICANT LOSSES EVERY YEAR since its inception. The Company EXPECTS TO CONTINUE TO INCUR LOSSES OVER THE NEXT SEVERAL YEARS and MAY NEVER ACHIEVE OR MAINTAIN PROFITABILITY.”

So let me get this straight, no one believes the CEO, whose words I’m quoting directly from the official prospectus, clearly stating that they don’t have the funds to continue the trials beyond £5.6m and only until January 2026?

I can’t wait for the FCA to look into all activity, especially that of the so-called LTHs and what was happening around the placings 😆😆😆

#triggered

What you going do to? Refer them to their own prospectus which I’ve quoted from directly? 😆😆😆

LOL. They don’t have enough money to progress the trials past the transfer and need to raise £5.6m I don’t think anyone needs to talk it down to buy in 😆😆😆

address this anticipated funding shortfall, the Group will require ADDITIONAL WORKING CAPITAL OF £5.6 MILLION BY THE END OF JANUARY 2026 just to continue its product development activities with a primary focus on HG-CT-1 through to the end of 2026. A FURTHER £10 MILLION will be required from 2027 to 2028.

The Group will have INSUFFICIENT WORKING CAPITAL AFTER ADMISSION and further funds WILL BE REQUIRED in the first quarter of 2026 simply to continue operations and complete Phase I trials of HG-CT-1 in adult and paediatric patients.

The Company states clearly that working capital will be INSUFFICIENT FOR ITS PRESENT REQUIREMENTS for at least the next 12 months. Following Admission, Directors expect an AGGREGATE FUNDING SHORTFALL OF £15.6 MILLION.

This is DESPITE THE MISLEADING HYPE AROUND A LOI IN ESTONIA and despite JustHereForFleecing being WRONG AGAIN yet still arguing with anyone who applies some sense.

They say: “The Company has incurred SIGNIFICANT LOSSES EVERY YEAR since its inception. The Company EXPECTS TO CONTINUE TO INCUR LOSSES OVER THE NEXT SEVERAL YEARS and MAY NEVER ACHIEVE OR MAINTAIN PROFITABILITY.”

The so called “LTHs” won’t be posting first thing as they rush to exit their positions and minimise their leverage at 8am on the dot.

Tells you everything you need to know.

From the companies official documentation. Unlike the hype this can be confirmed through the prospectus as fact. Seems rampers are getting posts removed.

To address this anticipated funding shortfall, the Group will require ADDITIONAL WORKING CAPITAL OF £5.6 MILLION BY THE END OF JANUARY 2026 just to continue its product development activities with a primary focus on HG-CT-1 through to the end of 2026. A FURTHER £10 MILLION will be required from 2027 to 2028.

The Group will have INSUFFICIENT WORKING CAPITAL AFTER ADMISSION and further funds WILL BE REQUIRED in the first quarter of 2026 simply to continue operations and complete Phase I trials of HG-CT-1 in adult and paediatric patients.

The Company states clearly that working capital will be INSUFFICIENT FOR ITS PRESENT REQUIREMENTS for at least the next 12 months. Following Admission, Directors expect an AGGREGATE FUNDING SHORTFALL OF £15.6 MILLION.

This is DESPITE THE MISLEADING HYPE AROUND A LOI IN ESTONIA and despite JustHereForFleecing being WRONG AGAIN yet still arguing with anyone who applies some sense.

They say: “The Company has incurred SIGNIFICANT LOSSES EVERY YEAR since its inception. The Company EXPECTS TO CONTINUE TO INCUR LOSSES OVER THE NEXT SEVERAL YEARS and MAY NEVER ACHIEVE OR MAINTAIN PROFITABILITY.”

#margincall #justhereforfleecing #socalledLTHswillberunningfordoorfirstthing

Yes, the CEO in an official prospectus 😆😆😆 telling you urgent funds neeeded and they don’t have enough to continue trials and need £5.6m by January is all made up 🫣

But apparently JustHereForFleecing said:

• They are “fully funded” - £5.6m NEEDED URGENTLY

• Estonia will earn millions - IT WONT

• The Made transfer will have no delays - IT HAS

• “It is not costing us much” - IT HAS

• It is “just an address change” - IT ISN’T

• And of course, “there will be no more specials”, despite him and his friends fleecing shareholders with their own special so far yet still leaving funding needs. - BOTH BROKERS STILL ON BOOKS

All while hyping it, selling into the spikes, and his followers, the “sheep,” blindly following every word he says despite being wrong time and time and time again and making things up as he goes depending on his position.

Yes, because a stark financial warning in official company documentation stating they don’t have enough cash to continue trials and will need £5.6 million IMMINENTLY is apparently less important than a tiny warrant exercise that won’t even touch the sides 😆😆

The huge dilution coming down the track is obviously less important too.

Also, nice alias, JustHereForFleecing.